Russell Investments Group Ltd. boosted its position in Arcus Biosciences Inc (NYSE:RCUS) by 32.9% in the 3rd quarter, HoldingsChannel reports. The firm owned 21,315 shares of the company’s stock after acquiring an additional 5,278 shares during the period. Russell Investments Group Ltd.’s holdings in Arcus Biosciences were worth $195,000 as of its most recent filing with the SEC.
A number of other institutional investors have also bought and sold shares of the stock. Aperio Group LLC acquired a new position in shares of Arcus Biosciences in the second quarter valued at $32,000. Meeder Asset Management Inc. raised its position in shares of Arcus Biosciences by 672.9% in the third quarter. Meeder Asset Management Inc. now owns 4,939 shares of the company’s stock valued at $46,000 after purchasing an additional 4,300 shares during the period. Susquehanna International Group LLP bought a new position in shares of Arcus Biosciences in the second quarter valued at about $119,000. Athanor Capital LP acquired a new stake in shares of Arcus Biosciences during the 2nd quarter worth about $126,000. Finally, GSA Capital Partners LLP lifted its stake in shares of Arcus Biosciences by 17.3% during the 2nd quarter. GSA Capital Partners LLP now owns 16,243 shares of the company’s stock worth $129,000 after buying an additional 2,392 shares during the last quarter. Institutional investors and hedge funds own 45.28% of the company’s stock.
Shares of NYSE RCUS opened at $8.21 on Wednesday. The stock’s fifty day moving average price is $8.15 and its two-hundred day moving average price is $8.25. Arcus Biosciences Inc has a one year low of $6.30 and a one year high of $13.77. The firm has a market cap of $379.25 million, a price-to-earnings ratio of -5.74 and a beta of 1.03.
A number of research analysts recently commented on RCUS shares. Zacks Investment Research lowered shares of Arcus Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, November 19th. Mizuho restated a “buy” rating and set a $22.00 price objective on shares of Arcus Biosciences in a research report on Monday, November 11th. Finally, SunTrust Banks started coverage on shares of Arcus Biosciences in a research report on Tuesday, November 12th. They set a “buy” rating and a $20.00 price objective for the company. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $17.35.
Arcus Biosciences Company Profile
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.
Featured Article: What is a good dividend yield?
Want to see what other hedge funds are holding RCUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcus Biosciences Inc (NYSE:RCUS).
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.